Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey.

Fiche publication

Date publication

janvier 2021

Journal

Therapeutic advances in musculoskeletal disease

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARTIN Thierry

Tous les auteurs :
Petitdemange A, Felten R, Sibilia J, Martin T, Arnaud L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34046091

Résumé

Antimalarial agents (AMs), mainly hydroxychloroquine (HCQ) and chloroquine, are the cornerstone of treatment of cutaneous and systemic lupus erythematosus. However, many aspects of AM prescription remain empirical. The aim of this study was to assess the modalities of AM prescription among physicians treating patients with lupus and to verify the assumption that AM use is heterogeneous and frequently at variance with international guidelines.